Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Brooklyn ImmunoTherapeutics, Inc. - Common Stock (NQ: BTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Brooklyn ImmunoTherapeutics, Inc. - Common Stock

Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be... 
From Stock News Now
Via AccessWire
Topics Cannabis
Exposures Cannabis
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are... 
From Access to Giving
Via AccessWire
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders
From Brooklyn ImmunoTherapeutics LLC
Via Business Wire
Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Brooklyn ImmunoTherapeutics Reports Inducement Grants
From Brooklyn ImmunoTherapeutics LLC
Via Business Wire
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc.
From Brooklyn ImmunoTherapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.